ClinicalTrials.Veeva

Menu

Opsin Receptors in Melasma

U

Universidad Autonoma de San Luis Potosí

Status

Completed

Conditions

Melasma

Treatments

Drug: Retinoic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT04417348
OPN3Mel

Details and patient eligibility

About

Melasma is a hyperpigmentation disorder that is probably exacerbated by visible light. Opsin receptors (OPN 1, 2, 3, 4 y 5) were described in the skin, being capable of activating melanogenesis induced by visible light. The aim of this study was to evaluate the expression of OPN in melasma skin and its changes following treatment with UV-Vis filter and 0.05% retinoic acid for 12 weeks.

Enrollment

15 patients

Sex

Female

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients diagnosed with melasma, of 18 years of age and older, without previous treatment or photoprotection measures within the previous 4 weeks, who had Melasma Activity and Severity Index (MASI) scores higher than 7

Exclusion criteria

  • pregnancy or nursing, menopause, coexistence of other pigmentation conditions, heat exposure, regular exercise, diet restriction, consumption of food supplements or any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months, and women who had given birth within 1 year

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

15 participants in 2 patient groups, including a placebo group

Retinoic Acid
Active Comparator group
Description:
patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
Treatment:
Drug: Retinoic acid
Sunscreen
Placebo Comparator group
Description:
patients with melasma treated with UV-Visible light filter alone
Treatment:
Drug: Retinoic acid

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems